Mergers & Growth Clinipace Worldwide (formerly Choice Pharma) combines forces with Accovion and dMed Global, creating a broader global footprint and expanded service capabilities that open cross-sell opportunities across regulatory, clinical, and post-approval research services.

Digital CRO Advantage As the first digital clinical research organization (dCRO) powered by the TEMPO eClinical platform, Clinipace offers streamlined study design, data capture, and regulatory planning that can be pitched to sponsors seeking efficiency, faster timelines, and integrated analytics.

Therapeutic Breadth With deep therapeutic expertise spanning cardiovascular, CNS, dermatology, oncology, immunology, infectious diseases, and vaccines, there are multiple cross-domain upsell paths for sponsors pursuing multi-therapeutic or combinational trial programs.

Financial Health Signals Historically active in financing rounds and notable revenue scale for a mid-market CRO, combined with growth via mergers, indicating investment readiness among clients for expanded scopes, capabilities, and global delivery models.

Strategic Partnerships Recent partnerships and leadership appointments point to a focus on expanding operations and client footprint, presenting opportunities to engage in strategic alliances, co-development programs, and larger, multi-regional trials.